SARS-CoV-2 B.1.617 Indian variants: are electrostatic potential changes responsible for a higher transmission rate?

Stefano Pascarella¹, Massimo Ciccozzi²*, Davide Zella³, Martina Bianchi¹, Francesca Benetti³, Francesco Broccolo⁴, Roberto Caudà³, Arnaldo Caruso⁶, Silvia Angeletti⁷*, Marta Giovanetti⁸, Antonio Cassone⁹

¹University of Rome I - Department of Biochemical Science; ²Medical Statistic and Molecular Epidemiology Unit, University of Biomedical Campus, Rome, Italy; ³Institute of Human Virology and Global Virus Network Center, Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD 21201, USA; ⁴Department of Clinical Medicine and Prevention, University of Milano-Bicocca; ⁵Istituto Clinica di Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy; ⁶Department of Microbiology and Virology, Spedali Civili, Piazzale Spedali Civili, 1, 25123, Brescia, Italy; ⁷Unit of Clinical Laboratory Science, University Campus Bio-Medico of Rome, Rome, Italy; ⁸Laboratório de Flavivírus, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil; ⁹Department of Genomics, Genetics and Biology, University of Siena, Siena, Italy.

* Denote equal contribution

*Correspondence: M.ciccozzi@unicampus.it, S.Angeletti@unicampus.it

Key words: SARS-CoV-2, B.1.617 variants, electrostatics potential changes

Abstract

Lineage B.1.617+, also known as G/452R.V3, is a recently described SARS-CoV-2 variant under investigation (VUI) firstly identified in October 2020 in India. As of May 2021, three sublineages labelled as B.1.617.1, B.1.617.2 and B.1.617.3 have been already identified, and their potential impact on the current pandemic is being studied. This variant has 13 amino acid changes, three in its spike protein, which are currently of particular concern: E484Q, L452R and P681R. Here we report a major effect of the mutations characterizing this lineage, represented by a marked alteration of the surface electrostatic potential (EP) of the Receptor Binding Domain (RBD) of the spike protein. Enhanced RBD-EP is particularly noticeable in the B.1.617.2 sublineage, which shows multiple replacements of neutral or negatively-charged amino acids with positively-charged amino acids. We here hypothesize that this EP change can favor the interaction between the B.1.617+
RBD and the negatively-charged ACE2 thus conferring a potential increase in the virus transmission.

**Introduction**

The Coronavirus Disease 19 (COVID-19), caused by the new coronavirus SARS-CoV-2, continues to spread worldwide, with more than 163 million infections and about 3.5 million deaths as of May 17th, 2021 (www.who.int). In order to fight this dreadful disease, several safe and efficacious vaccines against SARS-CoV-2 are being used with remarkable effectiveness in some countries and limited availability in others. In particular, the capacity of some countries to halt SARS-CoV-2 spread is still limited due to inadequate resources and vaccination infrastructures (1,2). In this scenario, several SARS-CoV-2 variants have been identified and have become a global threat. Some of them have been classified as variants of concern (VOCs) due to their mutations in the S1 subunit of the spike (S) protein, particularly in its receptor binding domain (RBD) (3-5). One of them, identified as B.1.1.7, also known as the UK variant, bears a substitution of asparagine with tyrosine on the position 501 and a deletion of two amino acids in the position 69-70 of the S1 subunit. This variant has quickly spread in several European countries to become globally dominant (5). Others VOCs have been isolated in South Africa and Brazil and have been studied for their enhanced contagiousness and resistance to neutralization by antibodies from convalescent and vaccine-recipient subjects (6-8) (Table 1). Quite recently, a new variant under investigation (VUI) has been isolated from Maharashtra, India, in a setting of highly diffusive epidemic with devastating proportions (. This variant, identified as B.1.617 carries several non-synonymous mutations. Two of them, the E484Q (or the P478K) and the L452R, are located in the RBD region, and they are critical site for the binding with ACE2. Initial data suggest these mutations could confer increased transmission and immune-evasion (9-11). Currently, B.1.617 comprises three subvariants, B.1.617.1-3, with different distribution of the mutations P478K and E484Q (Public Health England). Here we focus on biochemical and biophysical changes conferred to the B.1.617+ VUI by the P478K and E484Q mutations. We then compare these changes with other VOC in order to establish whether and to what extent those amino acid changes can influence the interaction of the Spike protein with ACE2, thus potentially affecting SARS-CoV-2 transmission and immune-escape properties.

**Methods**
In order to perform more robust analysis 3 different 3-dimensional structures of SARS-CoV-2 Spike Glycoprotein have been downloaded from Protein Data Bank with the following characteristics:

1. SARS-CoV-2 RBD in complex with neutralizing antibody CC12.3 (PDB code: 6XC4 chain A)
2. SARS-CoV-2 Spike Glycoprotein whole structure (PDB code: 6XR8 chain E)
3. SARS-CoV-2 RBD in complex with ACE2-B0AT1 (PDB code: 6M17 chain F).

The DynaMut server (12) has been used to predict the impact of mutations on protein stability analyzing the folding free energy ($\Delta\Delta G$) and the Vibrational movement ($\Delta\Delta S$), two crucial characteristics of the function and the molecular recognition of the protein. PyMol (PyMol, version 2.4) suite was utilized for in-silico mutagenesis and its Adaptive Poisson–Boltzmann Solver (APBS) plugin (13) has been used to calculate the electrostatic potential of the wild-type and VOCs SARS-CoV-2 Spike Receptor Binding Domain (RBD) and evaluate potential differences in terms of molecular interaction with ACE2 receptor. The results have been reported within a range between -5 kT/e and +5 kT/e.

Results

Protein stability

In silico prediction of the mutation impact on the RBD stability has been carried out with DynaMut. Three alternative RBD structures denoted by the PDB codes 6M17, 6M0J and 6XC4 have been tested. These structures display small differences in the conformation of loops, especially in the one inside the Receptor Binding Motif (RBM). According to the parameters of our in silico experiments, the output of DynaMut for mutant sites within loops differ depending on the starting loop conformation. For this reason, we used a normalized procedure, whereby the same mutation has been tested in each of the three different RBD structures. The effect on stability, de- or stabilization, has been evaluated following a majority criterion. Detailed results have been reported in Table 1.

Starting with position 501 within a loop in the RBD interacting with ACE2 receptor, we note that the mutation N501Y does not show any unambiguous structural effect and should be considered neutral (Table 1). Also, position 417 is within the interface $\alpha$-helix where Lys interacts with ACE2 Asp30. However, in this case, our results predict that both mutants (K417N and K417T) could
destabilize the protein and increase local flexibility. Similarly, Glu484 is in an interfacial loop and interacts with ACE2 Lys31. Again, our data predict that both mutations (E484K and E484Q) exert a destabilizing effect, with E484Q being the strongest. We note that Glutamic Acid is a polar, negatively charged, hydrophilic amino acid while Lysine is basic, chiral, charged and aliphatic amino acid and its ε-amino group often participates in hydrogen bonding, salt bridges and covalent interactions. Both mutants E484K and E484Q, would likely increase local molecular flexibility. L452 is in a short β-strand and it is exposed to the solvent. Apparently, it does not interact directly with ACE2. Mutation L452R is predicted to be destabilizing with increased local flexibility. Position 478 is in a loop in proximity of the ACE2 although not in direct contact with it. The mutation T478K is stabilizing and predicted to decrease local protein flexibility.

**Surface and interface analysis**

The entire set of mutations in position 417, 452, 478, 484 and 501 are in the Spike RBD at the interface with the ACE2 N-terminal helix (Figure 1). However, we note that the mutant positions 452, 478, 484 and 501 are within the RBM, containing residues that bind to ACE2. On the other hand, the mutant position 417 is located outside the motif (14).

According to our analysis, the mutations in position 417, 484 and 501 might alter the Spike binding affinity with the ACE2 receptor. In particular, the Tyr replacing Asn501 may form an aromatic interaction with ACE2 Tyr41, a hydrogen bond with ACE2 D38 and a potential cation-π interaction with ACE2 Lys353. In addition, substitutions of Glu484 with Lys or Gln may form hydrophobic interactions to Ile472, Gly482, Phe486, Cys488 and Tyr489. Our data also indicate that replacing Lys or Gln with Glu484 abolishes the interfacial salt bridge between Glu484 and ACE2 Lys31. Due to the fact that Lys417 is solvent-exposed and forms salt-bridge interactions with Asp30 of ACE2, replacement of Thr/Asn with Lys417 could abolish this interaction. Moreover, although the mutations in positions 452 and 478 are within the receptor binding motif, our analysis does not show a direct interaction with ACE2.

**Electrostatic potential.**

We note that a major, global effect of the mutations characterizing the Indian variants is represented by the alteration of the RBD surface electrostatic potential. In particular, in the lineage B.1.617.1 the uncharged and hydrophobic residue Leu452 changes to the positively charged residue Arg, and the negatively charged residue Glu484 is replaced by the uncharged residue Gln. On the other hand,
the B.1.617.2 lineage shares the same mutation in position 452, but it has another mutation in position 478 where the neutral residue Thr changes to the positively charged Lys. The presence of two positively charged residues in the variant B.1.617.2 increases the positive electrostatic potential surface (Figure 2).

Discussion

Given that SARS-CoV-2 variants are characterized by evolutionary and genetic changes accumulated in the genome, the use of new and improved phylodynamic techniques for the study of how epidemiological, immunological, and evolutionary processes contribute to shaping viral phylogenies is extremely important and useful. Here using a well-structured software workflow we provide evidence of a strong system able to carry out a quick, systematic and reproducible screening of the SARS-CoV-2 genome isolates. Protein mutations were identified by scanning high-quality SARS-CoV-2 genomes variants downloaded from GISAID databank (15). We reasoned that the most likely health-threatening properties of SARS-CoV-2 VOC rely on fine biochemical and biophysical changes that eventually impact the RBD interaction with the ACE2 receptor present on the host’s cell surface. We thus characterized B.1.617+ SARS-CoV-2 VUI using in-silico methods capable of predicting the effect of mutations on S-RBD protein stability and its electrostatic potential. The B.1.617+ mutations have been investigated by comparing most of the already known mutations of previously reported VOCs (16). To further justify our assumption, we note that the intensely investigated D614G substitution of the spike protein, early reported in Italian isolates (17, 18, 19), and subsequently attributed with increased virus transmissibility (20) was found to enhance the protein torsional ability and potentially affecting its stability (20).

Regarding the commonly denominated Indian variants, these constitute the new SARS-CoV-2 lineage B.1.617, which is actually composed by a family of three sub-variants, namely B.1.617.1, B.1.617.2 and B.1.617.3. This lineage, which emerged in India in October 2020 has since spread to other countries, particularly in UK, in settings with high density of residents immigrants from India. Data from Public Health England registry shows that the subvariant B.1.617.2 has become epidemiologically prevalent (21). Because of its amino-acid composition, the variant has been designed as B.1.617+ by the WHO (22).

A dichotomic behavior is observed with variant B.1.617.2. On the one hand, it lacks the mutation “E484Q” which is present in the other two lineages, and this absence seems to confer a certain
degree of resistance to antibody neutralization. On the other hand, this subvariant has a mutation at
the site 478 where a lysine replaces the proline. Of note, variant B.1.617.2 is indeed characterized
by a major shift towards increased positive electrostatic potential because of three amino acids
changes from negative or neutral to clearly positive charge, as shown in the Results section.

Sub-variants B.1.617.1 and B.1.617.3 have both the double mutations E484Q and the L452R.
Although initially believed to enhance the antibody-escape potential, it has been shown that the
B.1.617.1 subvariant is pretty neutralized by the majority of sera from convalescent individuals and
all sera from vaccinated subjects (24). Nonetheless, this variant has been shown to be more
pathogenic than the B.1.1.7 variant in an experimental model of SARS-CoV-2 infection in hamsters
(25).

Our data indicate that most of the mutants are predicted to destabilize the RBD structure, except for
T478K. It is thus conceivable that with destabilization comes altered binding affinity to ACE2 and
to neutralizing antibodies. As noticed above, the influence of the mutations on the Spike surface
properties is particularly evident in the B.1.617+ lineage, particularly for the B.1.617.2 lineage
component, where the positive electrostatic surface potential is markedly increased. This may favor
RBD interaction with the negatively charged ACE2 (26), which in turn would then increase affinity
for the ACE2 receptor. All of these changes have the potential to eventually modify infectivity,
pathogenicity and virus spread. Regarding differential binding to neutralizing antibodies, previous
studies suggested that VOCs RBDs changes in the electrostatic potential surface could induce
SARS-CoV-2 antibody evasion and even single amino acid changes that marginally affect ACE2
affinity could greatly influence nAbs affinity (27). Several factors have been demonstrated to affect
the impact of VOCs. For example, it has been observed an increased effect at pH associated with
nasal secretions (from 5.5 to 6.5) (28). For this reason, additional experiments both in vitro and in
vivo are needed to establish the biological significance of SARS-CoV-2 mutations and how the
interactions between mutations and local cellular microenvironment influences the clinical outcome
and the transmission dynamics of this virus.

Acknowledgments

SP has been partially supported by the Sapienza grant RP120172B49BE24. Authors are grateful to
Alice Vinciguerra for her precious assistance. We also would like to thank all the authors who have
kindly deposited and shared genome data on GISAID.
References

1. C. Wang, P.W. Horby, F.G. Hayden, G.F. Gao, A novel coronavirus outbreak of global health concern, Lancet (2020 Jan 29). Epub ahead of print, https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30185-9/fulltext.

2. Mullard A. How COVID vaccines are being divided up around the world. Nature 2020; published online Nov 30. https://doi.org/10.1038/d41586-020-03370-6

3. Fontanet A, Autran B, Lina B, Kieny MP, Abdol Karim SS, Shridar D. SARS-CoV-2 variants and ending the COVID-19 pandemic. Lancet, 2021, 397:952-954

4. Chen Y, Guo Y, Pan Y, Zhao ZJ. Structure analysis of the receptor binding of 2019-nCoV. Biochem. Biophys. Res. Commun. 2020, 525:135-140.

5. Galloway, Summer E., Prabasaj Paul, Duncan R. MacCannell, Michael A. Johansson, John T. Brooks, Adam MacNeil, Rachel B. Sláton, et al. 2021. Emergence of SARS-CoV-2 B.1.1.7 Lineage - United States, December 29, 2020-JanXar12, 2021. MMWR. Morbidity and Mortality Weekly Report 70 (3): 95±99.

6. Voysey M, Costa Clemens SA, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2020; 397: 99–111.

7. Volz E, Mishra S, Chand M, et al. Transmission of SARS-CoV-2 lineage B.1.1.7 in England: insights from linking epidemiological and genetic data. medRxiv 2021; published online Jan 4. https://doi.org/10.1101/2020.12.30.20249034 (preprint)
8. Davies NG et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science 10.1126/science.abg3055 (2021).

9. Pragya D. Yadav, Sreelekshmy Mohandas, Anita M Shete, Dimpal A Nyayanit, Nivedita Gupta, et al. SARS CoV-2 variant B.1.617.1 is highly pathogenic in hamsters than B.1 variant. bioRxiv preprint doi: https://doi.org/10.1101/2021.05.05.442760

10. Isabella Ferreira1, Rawlings Datir1, Guido Papa Steven Kemp, Bo Meng Partha4 Rakshit4, et al. SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited antibodies. BioRxiv preprint doi: https://doi.org/10.1101/2021.05.08.443253; t

11. Markus Hoffmann, Heike Hofmann-Winkler, Nadine Krüger, Amy Kempf, Inga Nehlmeier, Luise Graichen, et al. SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades 2 antibodies induced by infection and vaccination. doi: bioRxiv preprint https://doi.org/10.1101/2021.05.04.442663;

12. Rodrigues CH, Pires DE, Ascher DB. DynaMut: predicting the impact of mutations on protein conformation, flexibility and stability. Nucleic Acids Res. 2018 Jul 2;46(W1):W350-W355. doi: 10.1093/nar/gky300. PMID: 29718330; PMCID: PMC6031064.

13. Baker NA, Sept D, Joseph S, Holst MJ, McCammon JA. Electrostatics of nanosystems: application to microtubules and the ribosome. Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10037-41. doi: 10.1073/pnas.181342398. Epub 2001 Aug 21. PMID: 11517324; PMCID: PMC56910.

14. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L, Wang X. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020 May;581(7807):215-220. doi: 10.1038/s41586-020-2180-5. Epub 2020 Mar 30. PMID: 32225176.

15. Bianchi M, Borsetti A, Ciccozzi M, Pascarella S. SARS-Cov-2 ORF3a: Mutability and function. Int J Biol Macromol. 2021;170:820-826. doi:10.1016/j.ijbiomac.2020.12.142

16. Tegally, H., Wilkinson, E., Giovanetti, M. et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature 592, 438–443 (2021). https://doi.org/10.1038/s41586-021-03402-9

17. Benvenuto D, Demir, A B, Giovanetti M, Bianchi M, Angeletti S Pascarella S et al. Evidence for mutations in SARS-CoV-2 Italian isolates potentially affecting virus transmission.
18. Korber, B. et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell 182, 812–827 (2020).

19. Pachetti M, Marini B, Benedetti F, Giudici F, Mauro E, Storici P, Masciovecchio C, Angeletti S, Ciccozzi M, Gallo RC, Zella D, Ippodrino R. Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant. J Transl Med. 2020 Apr 22;18(1):179. doi: 10.1186/s12967-020-02344-6. PMID: 32321524; PMCID: PMC7174922.

20. Plante, J.A., Liu, Y., Liu, J. et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature (2020). https://doi.org/10.1038/s41586-020-2895-3.

21. Variants: distribution of cases data - GOV.UK (available at: https://www.gov.uk/government/publications/covid-19-variants-genomically-confirmed-case-numbers/variants-distribution-of-cases-data).

22. WHO, May 2021. Available at: https://www.who.int/csr/don/31-december-2020-sars-cov2-variants/en/

23. Zhou, D., Dejnirattisai, W., Supasa, P., Liu, C., Mentzer, A.J., Ginn, H.M., et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine induced sera, Cell (2021), doi: https://doi.org/10.1016/j.cell.2021.02.037.

24. Doria-Rose N, Suthar MS, Makowski M, O'Connell S, McDermott AB, Flach B, Ledgerwood JE, Mascola JR, Graham BS, Lin BC, O'Dell S, Schmidt SD, Widge AT, Edara VV, Anderson EJ, Lai L, Floyd K, Rouphael NG, Zamitsyna V, Roberts PC, Makhene M, Buchanan W, Luke CJ, Beigel JH, Jackson LA, Neuzil KM, Bennett H, Leav B, Albert J, Kunwar P; mRNA-1273 Study Group. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. N Engl J Med. 2021 Apr 6. doi: 10.1056/NEJMc2103916. Epub ahead of print. PMID: 33822494.

25. Abdelnabi R., et al. Comparative infectivity and pathogenesis of emerging SARS-CoV-2 variants in Syrian 2 hamsters. BioRxiv, 2021.

26. Amin SA, Jha T. Fight against novel coronavirus: A perspective of medicinal chemists. Eur J Med Chem. 2020;201:112559. doi:10.1016/j.ejmech.2020.112559
27. Ferraz M; Moreira E; Coelho DF; Wallau G, Lins R. SARS-CoV-2 VOCs Immune Evasion from Previously Elicited Neutralizing Antibodies Is Mainly Driven by Lower Cross-Reactivity Due to Spike RBD Electrostatic Surface Changes. ChemRxiv. Preprint. 2020
https://doi.org/10.26434/chemrxiv.14343743.v1

28. Scott P. Morton, Joshua L. Phillips. Computational Electrostatics Predict Variations in SARS-CoV-2 Spike and Human ACE2 Interactions. bioRxiv 2020.04.30.071175; doi: https://doi.org/10.1101/2020.04.30.071175

**Figure legends**

**Figure 1.** Comparison between the wild-type and variant Spike RBDs. Protein surface is coloured according to the electrostatic potential. Colour scale ranges from -5 kT/e (red) to +5kT/e (blue) as reported by the bar under the wild-type RBD. Position of the mutant sites are indicated by a circle and an attached label. Red arrows mark the area of increased positive potential in the RBD variants.

**Figure 2.** Ribbon model of the interface between ACE2 (deeptea) and RBD (orange). Side chains of relevant residues are displayed as stick models and labelled. The two mutations at the RBD sits 417 and 484 have been simultaneously displayed.
India (lineage B1.617.1) India (lineage B1.617.2)

South African

Brazil

Wild-type

Q484 R452

K478

K484

N417

Y501

E484 K417 L452 N501

T478

K417

N417

Y501

K484
Table 1. Dynamut results

| Mutant sites | ΔΔG (kcal/mol)a | ΔΔS (kcal/mol•K)b |
|--------------|----------------|------------------|
|              | 6M17 | 6M0J | 6XC4 | 6M17 | 6M0J | 6XC4 |
| N501Y        | 0.089 | -0.272 | 0.089 | -0.162 | 0.138 | -0.312 |
| K417N        | -0.399 | -0.651 | -1.174 | 0.487 | 0.659 | 0.347 |
| K417T        | -0.152 | -0.566 | -0.832 | 0.198 | 0.507 | 0.193 |
| E484K        | 0.087 | -0.101 | -0.109 | -0.075 | 0.171 | 0.336 |
| E484Q        | 0.399 | -0.644 | -0.755 | -0.084 | 0.151 | 0.189 |
| L452R        | -0.417 | -0.319 | -0.462 | 0.150 | 0.059 | -0.016 |
| T478K        | -0.334 | 1.003 | 0.257 | 0.111 | -0.385 | -0.152 |

a) Free energy difference (ΔΔG) between wild-type and mutant structure. Negative values indicate destabilization.

b) Vibrational Entropy difference (ΔΔS) between wild-type and mutant structure. Positive values indicate increased flexibility.